

02-61000-22

Original Effective Date: 06/15/00

Reviewed: 01/22/26

Revised: 02/15/26

Subject: Vagus Nerve Stimulation

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Updates			

DESCRIPTION:

Stimulation of the vagus nerve can be performed by means of an implantable stimulator within the carotid artery sheath. This technique has been proposed as a treatment for refractory seizures, depression, and other disorders.

Transcutaneous vagus nerve stimulation (tVNS) has been investigated as a non-invasive alternative to surgery for implantable vagus nerve stimulators. tVNS involves stimulation of superficial branches of the vagus nerve on the ear. Investigators have hypothesized that direct stimulation of the afferent nerve fibers on the ear area with afferent vagus nerve distribution may produce an effect similar to VNS with an implanted stimulator.

Vagus nerve blocking therapy for obesity consists of an implantable device that delivers electrical stimulation to branches of the vagus nerve on the anterior abdominal wall. The intent is to intermittently block signals to the intra-abdominal vagus nerve to disrupt hunger sensations and induce feelings of satiety.

Noninvasive vagus nerve stimulation (nVNS) is thought to affect central and peripheral neural circuits that subserve pain and autonomic physiology. The mechanism is not clear, and thus nVNS remains an area of intense investigation.

Summary and Analysis of Evidence: An UpToDate review titled “Vagus nerve stimulation therapy for the treatment of epilepsy” (Schachter, Sirven; 2024) states “(i)n general, vagus nerve stimulation (VNS) therapy is considered a valid treatment option for children and adults with well-documented medically refractory seizures who are opposed to intracranial surgery, are not candidates, or whose medically refractory seizures were not substantially improved by prior intracranial epilepsy surgery. Although there are limited randomized studies in other age groups and seizure types, observational studies reviewed suggest that the benefits of VNS may extend to a broad range of seizure types. The effectiveness of VNS does not appear to vary significantly based on age, neurologic comorbidity, cause

of epilepsy, location of the brain from which seizures arise, or epilepsy syndrome. Identification of factors that accurately predict a clinical response to VNS has been elusive. Although VNS is effective for seizures that originate from any lobe of the brain, one study found that seizures arising from the frontal lobes responded better than seizures arising from the temporal region. Other studies have suggested that VNS may be more effective in patients who have had epilepsy for a shorter period of time and in patients with seizures beginning after one year of age. Earlier age of epilepsy onset is also a predictor of medical intractability. Further studies are needed to identify predictive factors associated with a response to VNS." An UpToDate review titled "Bipolar disorder in adults: Overview of neuromodulation procedures" (Holtzheimer, 2024) states "(i)t is not known if VNS is efficacious as adjunctive treatment for bipolar disorder due to the limited and low quality data that are available." "It is not known whether VNS causes treatment-emergent mania or hypomania in patients with bipolar depression, given the paucity of randomized trials comparing active with sham VNS, and that patients can switch to mania/hypomania in the absence of or despite treatment. In a 10-week randomized trial that included 23 patients with bipolar major depression, one patient receiving active VNS switched to mania. An observational study also reported a case in which a patient with bipolar major depression developed treatment-emergent mania." UpToDate review "Unipolar depression in adults: Overview of neuromodulation procedures" (Holtzheimer, 2024) states "... noninvasive, investigational neuromodulation procedures include ... transcutaneous vagus nerve stimulation." An UpToDate review titled "Cluster headache: Treatment and prognosis" (May, 2024)" states "(w)hen chronic cluster headache is unresponsive to medical treatments, various surgical interventions and neurostimulation techniques are potential treatment options, though none are clearly established as effective. In such cases, it is particularly important to exclude potential causes of secondary cluster headache. Neurostimulation techniques, including ... vagus nerve stimulation, appear promising but remain investigational." Sant'Anna et al (2021) conducted a systematic review and meta-analysis on clinical trials comparing VNS with medical therapy for the management of chronic heart failure with reduced ejection fraction. Four RCTs and 3 prospective studies were identified (N=1263). Only data from the 4 RCTs were included in the meta-analysis. The certainty of the evidence based on GRADE characteristics was reported as high for all outcomes. The meta-analysis found significant improvements in New York Heart Association (NYHA) functional class, quality of life, 6-minute walk test, and N-terminal-pro brain natriuretic peptide levels in patients treated with VNS compared to sham. The authors acknowledged several limitations, including "(1) small number of studies included, which demonstrate the paucity of RCTs to evaluate the effects of vagal stimulation in this specific population, (2) heterogeneity in the objectives or primary outcomes of each study, and (3) no evidence regarding the etiology of the HF in most of the studies, something we know that may elicit different prognosis." Ramos-Castaneda et al (2022) published a systematic review evaluating VNS on upper limb motor recovery after stroke. Three RCTs by Dawson et al (2021) and Kimberley et al (2019) were pooled for the analysis evaluating the role of implanted VNS. Results demonstrated that implanted VNS improved upper limb motor function based on Fugl-Meyer Assessment-Upper Extremity (FMA-UE) score when compared to control. The authors stated "(t)he systematic review and meta-analysis have some limitations ... that include the number of clinical trials was very low and one of the included studies had no comparison group; ... a high statistical heterogeneity between studies; ... <and> some sources of heterogeneity that could not be evaluated,<e.g.,> the day of primary outcome evaluation, physical rehabilitation protocol parameters, the severity of the lesion, and the vascular region affected by the stroke, among others." VNS has been investigated with small pilot studies or studies evaluating the mechanism of disease for several

conditions, including essential tremor (Marano et al, 2024; Handforth et al, 1998), fibromyalgia (Cai et al, 2024; Lange et al, 2011) and tinnitus (Wu et al, 2024; de Ridder et al, 2014). None of these studies are sufficient to draw conclusions on the effect of VNS on these conditions. Lorupolu et al (2024) reviewed 29 studies of vagus nerve stimulation for treatment of stroke, traumatic brain injury (TBI) and spinal cord injury (SCI); 11 were animal models of stroke, TBI, and SCI, and eight involved humans with stroke. While there was heterogeneity in methods of delivering VNS with respect to rehabilitation therapy in animal studies and human non-invasive studies, a similar methodology was used in all human-invasive VNS studies. In animal studies, pairing VNS with rehabilitation therapy consistently improved motor outcomes compared to controls. Except for one study, all human invasive and non-invasive studies with controls demonstrated a trend toward improvement in motor outcomes compared to sham controls post-intervention. However, compared to non-invasive, invasive VNS studies reported severe adverse events such as vocal cord palsy, dysphagia, surgical site infection, and hoarseness of voice, which were found to be related to surgery. The authors concluded that their review “suggests that VNS (non-invasive or invasive) paired with rehabilitation can improve motor outcomes after stroke in humans. Hence, VNS human studies are needed in people with TBI and SCI. There are risks related to device implantation to deliver invasive VNS compared to non-invasive VNS. Future human comparison studies are required to study and quantify the efficacy vs. risks of paired VNS delivered via different methods with rehabilitation, which would allow patients to make an informed decision.” The use of VNS for treatment of rheumatoid arthritis (RA) by various routes has been studied by several groups (Bonaz, B, 2024; Baker et al, 2023; Marsal et al, 2021). Authors believe results are promising, however, clinical efficacy results of fully completed studies are awaited with interest.

POSITION STATEMENT:

Vagus nerve stimulation **meets the definition of medical necessity** as a treatment of medically refractory seizures, defined as seizures that occur despite therapeutic levels of antiepileptic drugs or seizures that cannot be treated with therapeutic levels of antiepileptic drugs, because of intolerable adverse events of these drugs.

The available scientific evidence does not support conclusions regarding the effectiveness of vagus nerve stimulation for all other indications. Vagus nerve stimulation is considered **experimental or investigational** for all other conditions, including but not limited to the following:

- Depression
- Heart failure
- Upper limb impairment due to stroke
- Essential tremor
- Headache
- Fibromyalgia
- Tinnitus
- Traumatic brain injury
- Chronic autoimmune diseases (e.g., rheumatoid arthritis)

Vagus nerve blocking therapy (e.g., VBLOC®) is considered **experimental or investigational** for all indications, including but not limited to the treatment of obesity. Data in published medical literature are inadequate to permit scientific conclusions on long-term and net health outcomes.

The use of **transcutaneous vagus nerve stimulation (tVNS)** (nonimplantable vagus nerve stimulation device) (e.g., Stivax, GammaCore, and Gammacore Sapphire stimulators) is considered **experimental or investigational** for the treatment of any condition, as there is insufficient clinical evidence to permit conclusions on net health outcomes.

BILLING/CODING INFORMATION:

CPT Coding:

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct OR inductive coupling; with connection to a single electrode array
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct OR inductive coupling; with connection to 2 or more electrode arrays
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve
64568	Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator
64569	Revision or replacement of cranial nerve (e.g., vagus nerve) neurostimulator electrode array, including connection to existing pulse generator
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator
0908T	Open implantation of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed (e.g., SetPoint System) (investigational)
0909T	Replacement of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed (e.g., SetPoint System) (investigational)
0910T	Removal of integrated neurostimulation system, vagus nerve (e.g., SetPoint System) (investigational)
0911T	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; without programming by physician or other qualified health care professional (e.g., SetPoint System) (investigational)
0912T	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; with simple programming by physician or other qualified health care professional (e.g., SetPoint System) (investigational)

HCPCS Coding:

C1607	Neurostimulator, integrated (implantable), rechargeable with all implantable and external components including charging system (investigational)
E0735	Non-invasive vagus nerve stimulator (e.g., gammaCore Sapphire™) (investigational)

REIMBURSEMENT INFORMATION:

Refer to sections entitled [POSITION STATEMENT](#) and [PROGRAM EXCEPTIONS](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage Products: The following National Coverage Determination (NCD) was reviewed on the last guideline reviewed date: VAGUS Nerve Stimulation (VNS) (160.18) located at cms.gov.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

DEFINITIONS:

Epilepsy: recurrent, unprovoked paroxysmal transient disturbances of brain function that may be manifested as episodic impairment or loss of consciousness, abnormal motor phenomena, psychic or sensory disturbances, or perturbation of the autonomic nervous system.

Seizure: a transient disturbance of cerebral function due to an abnormal paroxysmal neuronal discharge in the brain.

Vagus nerve (nervus vagus): tenth cranial nerve; supplies sensory fibers to the ear, tongue, pharynx, and larynx, motor fibers to the pharynx, larynx, and esophagus, and parasympathetic and visceral afferent fibers to thoracic and abdominal viscera.

RELATED GUIDELINES:

[Gastric Electrical Stimulation, 01-91000-04](#)

OTHER:

None applicable.

REFERENCES:

1. AHRQ National Guideline Clearinghouse. Guideline Summary NGC-3925. The diagnosis and management of the epilepsies in adults and children in primary and secondary care. London (UK): Royal College of General Practitioners; 2004 Oct.
2. AHRQ National Guideline Clearinghouse. Guideline Summary NGC-7711. VA/DoD clinical practice guideline for management of major depressive disorder (MDD). Washington (DC): Department of Veteran Affairs, Department of Defense; 2009 May.
3. AHRQ National Guideline Clearinghouse. Guideline Summary NGC-8093. Practice guideline for the treatment of patients with major depressive disorder, third edition. Arlington (VA): American Psychiatric Association (APA); 2010 Oct.
4. AHRQ National Guideline Clearinghouse. Guideline Summary NGC-8696. Care of the patient with seizures. Second edition. Glenview (IL): American Association of Neuroscience Nurses; 2009 Dec.
5. AHRQ National Guideline Clearinghouse. Guideline Summary NGC-8985. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care.

London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 (Clinical guideline; no. 137).

6. American Headache Society. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. ISSN 0017-8748 Headache doi: 10.1111/head.12866 VC 2016. Published by Wiley Periodicals, Inc.
7. American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder. *Am J Psychiatry* 2000 Apr; 157(4 Suppl): 1-45.
8. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). *Am J Psychiatry*. 2002 Apr; 159(4 Suppl): 1-50.
9. Andalib S, Divani AA, Ayata C, Baig S, Arsava EM, Topcuoglu MA, Cáceres EL, Parikh V, Desai MJ, Majid A, Girolami S, Di Napoli M. Vagus Nerve Stimulation in Ischemic Stroke. *Curr Neurol Neurosci Rep*. 2023 Dec;23(12):947-962. doi: 10.1007/s11910-023-01323-w. Epub 2023 Nov 27. PMID: 38008851.
10. Apovian CM, Shah SN, Wolfe BM, et al. Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial. *Obes Surg*. 2017;27(1):169–176. Doi:10.1007/s11695-016-2325-7.
11. Bajbouj M. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. *J Clin Psychopharmacol*. 2010 Jun;30(3):273-81.
12. Baker MC, Kavanagh S, Cohen S, Matsumoto AK, Dikranian A, Tesser J, Kivitz A, Alataris K, Genovese MC. A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis. *Arthritis Rheumatol*. 2023 Dec;75(12):2107-2115. doi: 10.1002/art.42637. Epub 2023 Nov 9. PMID: 37390360.
13. Ben-Menachem E, Revesz D, Simon BJ, Silberstein S. Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability. *Eur J Neurol*. 2015 Sep;22(9):1260-8.
14. Berry SM, Broglio K, Bunker M, Jayewardene A, Olin B, Rush AJ. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. *Med Devices (Auckl)*. 2013;6:17-35.
15. Blue Cross and Blue Shield Association. Technology Evaluation Center (TEC). Chronic Vagus Nerve Stimulation for Treatment of Seizures. TEC Assessments 1998, Tab 9.
16. Blue Cross and Blue Shield Association. Technology Evaluation Center (TEC). Vagus Nerve Stimulation for Treatment-Resistant Depression. TEC Assessments 2005, Volume 20, No.8.
17. Blue Cross Blue Shield Association Evidence Positioning System®. 7.01.20 - Vagus Nerve Stimulation, 03/25.
18. Blue Cross Blue Shield Association Evidence Positioning System®. 7.01.150 - Vagus Nerve Blocking Therapy for Treatment of Obesity (Archived 03/21).
19. Blue Cross Blue Shield of Florida TEC Assessment Summary. Vagus Nerve Stimulation for Treatment of Epilepsy, 03/09/00.
20. Bonaz B. A novel neuroimmune modulation system for the treatment of rheumatoid arthritis. *Bioelectron Med*. 2024 Apr 3;10(1):9. doi: 10.1186/s42234-024-00142-9.
21. California Technology Assessment Forum (CTAF). Vagal Nerve Stimulation for Treatment Resistant Depression. Technology Assessment. San Francisco, CA: February 15, 2006.
22. Carpenter LL. Neurostimulation in resistant depression. *J Psychopharmacol*. 2006 May; 20 (3 Suppl): 35-40.
23. Center for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD) L33777. Noncovered Services (10/01/15) (Retired 07/01/20).

24. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) Vagus Nerve Stimulation (VNS) 160.18 (02/15/19).
25. Choi TY, Kim J, Koo JW. Transcutaneous auricular vagus nerve stimulation in anesthetized mice induces antidepressant effects by activating dopaminergic neurons in the ventral tegmental area. *Mol Brain*. 2024 Nov 27;17(1):86. doi: 10.1186/s13041-024-01162-x.
26. ClinicalTrials.gov. Vagus Nerve Stimulation for Treating Adults With Severe Fibromyalgia. NCT00294281. University of Medicine and Dentistry New Jersey. 2011.
27. ClinicalTrials.gov. Vagus Nerve Stimulation in Rheumatoid Arthritis. NCT00859859. North Shore Long Island Jewish Health System. 2011.
28. ClinicalTrials.gov. Vagal Nerve Stimulation and Glucose Metabolism. NCT01117311. Mayo Clinic. 2011.
29. ClinicalTrials.gov. Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia (02VNS2009). NCT01176721. Cerbomed GmbH. 2011.
30. ClinicalTrials.gov. Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease (VNS). NCT01569503. University Hospital, Grenoble. 2012.
31. ClinicalTrials.gov. Vivistim Registry for Paired VNS Therapy (GRASP) (GRASP). NCT05301140. MicroTransponder Inc. July 2022.
32. ClinicalTrials.gov. Paired Vagus Nerve Stimulation (VNS) With Rehabilitation for Upper Limb Function Improvement After Stroke. NCT01669161. MicroTransponder Inc. October 2016.
33. ClinicalTrials.gov. VNS During Rehabilitation for Improved Upper Limb Motor Function After Stroke. NCT02243020. MicroTransponder Inc. September 2022.
34. ClinicalTrials.gov. Pivotal Study of VNS During Rehab After Stroke (VNS-REHAB) (VNS-REHAB). NCT03131960. MicroTransponder Inc. July 2022. Sponsor: MicroTransponder Inc.
35. ClinicalTrials.gov. Safety and Feasibility of Paired Vagus Nerve Stimulation With Rehabilitation for Improving Upper Extremity Function in People With Cervical Spinal Cord Injury. NCT05601661. MicroTransponder Inc. November 2022.
36. Conway CR, Aaronson ST, Sackeim HA, George MS, Zajecka J, Bunker MT, Duffy W, Stedman M, Riva-Posse P, Allen RM, Quevedo J, Berger M, Alva G, Malik MA, Dunner DL, Cichowicz I, Banov M, Manu L, Nahas Z, Macaluso M, Mickey BJ, Sheline Y, Kriedt CL, Lee YL, Gordon C, Shy O, Tran Q, Yates L, Rush AJ. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. *Brain Stimul*. 2025 May-Jun;18(3):676-689. doi: 10.1016/j.brs.2024.12.1191. Epub 2024 Dec 18.
37. Conway CR, Sheline YI, Chibnall JT, George MS, Fletcher JW, Mintun MA. Cerebral blood flow changes during vagus nerve stimulation for depression. *Psychiatry Res*. 2006 Mar 31; 146(2): 179-84.
38. Dawson J, Liu CY, Francisco GE, Cramer SC, et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. *Lancet*. 2021 Apr 24;397(10284):1545-1553. doi: 10.1016/S0140-6736(21)00475-X.
39. Dawson J, Engineer ND, Cramer SC, Wolf SL, et al. Vagus Nerve Stimulation Paired With Rehabilitation for Upper Limb Motor Impairment and Function After Chronic Ischemic Stroke: Subgroup Analysis of the Randomized, Blinded, Pivotal, VNS-REHAB Device Trial. *Neurorehabil Neural Repair*. 2022 Oct 13:15459683221129274. doi: 10.1177/15459683221129274. Epub ahead of print.
40. Dawson J, Engineer ND, Prudente CN, Pierce D, et al. Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Stroke: One-Year Follow-up. *Neurorehabil Neural Repair*. 2020 Jul;34(7):609-615. doi: 10.1177/1545968320924361. Epub 2020 Jun 1.

41. Dawson J, Pierce D, Dixit A, Kimberley TJ, et al. Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. *Stroke*. 2016 Jan;47(1):143-50. doi: 10.1161/STROKEAHA.115.010477. Epub 2015 Dec 8.
42. de Ridder D, Vanneste S, Engineer ND, Kilgard MP. Safety and efficacy of vagus nerve stimulation paired with tones for the treatment of tinnitus: a case series. *Neuromodulation*. 2014 Feb;17(2):170-9. doi: 10.1111/ner.12127. Epub 2013 Nov 20.
43. de Coo IF, Marin JC, Silberstein SD, et al. Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. *Cephalalgia*. 2019 Jul;39(8):967-977. doi: 10.1177/0333102419856607. Epub 2019 Jun 10.
44. Deuchars SA, Lall VK, Clancy J, et al. Mechanisms underpinning sympathetic nervous activity and its modulation using transcutaneous vagus nerve stimulation. *Exp Physiol*. 2018;103(3):326–331. Doi:10.1113/EP086433.
45. Dunner DL, Rush AJ, Russell JM, Burke M, Woodard S, Wingard P, Allen J. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. *J Clin Psychiatry*. 2006 May; 67(5): 688-95.
46. ECRI. Clinical Evidence Assessment. Vivistim Paired VNS System (MicroTransponder, Inc.) for Improving Upper Limb Function after Stroke. © September 2021 ECRI.
47. ECRI. Custom Hotline Response. Implantable Vagus Nerve Stimulator for Epilepsy. Plymouth Meeting, PA: ECRI. 03/07/08.
48. ECRI. Custom Hotline Response. Implantable Vagus Nerve Stimulator for Treatment-resistant Depression. Plymouth Meeting, PA: ECRI. 05/01/07.
49. ECRI. Target Database. Target Report 80. Implantable Vagus nerve stimulator for treatment resistant depression. Plymouth Meeting, PA: ECRI. May 2007.
50. ECRI Institute Health Technology Forecast: Vagus Nerve Stimulation for Treating Chronic Heart Failure. 29 January 2013.
51. ECRI Institute Health Technology Forecast: Vagus Nerve Blocking for Treating Obesity. 02 May 2011.
52. Fisher RS, Handforth A. Reassessment: Vagus nerve stimulation for epilepsy: A Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Copyright © 1999 by the American Academy of Neurology.
53. Fochtmann, LJ & Gelenberg, AJ. Guideline Watch: practice guideline for the treatment of patients with major depressive disorder, 2nd Edition. Arlington (VA): American Psychiatric Association; 2005 Winter. 9 p.
54. Frangos E, Komisaruk BR. Access to Vagal Projections via Cutaneous Electrical Stimulation of the Neck: fMRI Evidence in Healthy Humans. *Brain Stimul*. 2017 Jan-Feb;10(1):19-27. doi: 10.1016/j.brs.2016.10.008. Epub 2016 Oct 20.
55. Gaul C, Diener HC, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube A; PREVA Study Group. Non-invasive vagus nerve stimulation for PREvention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. *Cephalalgia*. 2016 May;36(6):534-46. doi: 10.1177/0333102415607070. Epub 2015 Sep 21.
56. Gaul C, Magis D, Liebler E, Straube A. Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study. *J Headache Pain*. 2017 Dec;18(1):22. doi: 10.1186/s10194-017-0731-4. Epub 2017 Feb 14.
57. George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner D, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. *Biol Psychiatry*. 2005 Sep 1; 58(5): 364-73.

58. Gil K, Bugajski A, Thor P. Electrical Vagus Nerve Stimulation Decreases Food Consumption and Weight Gain in Rats Fed a High-fat Diet. *Journal of Physiology and Pharmacology* 2011, 62, 6, 637-646.
59. Goadsby PJ, de Coo IF, Silver N, Tyagi A, Ahmed F, Gaul C, Jensen RH, Diener HC, Solbach K, Straube A, Liebler E, Marin JC, Ferrari MD; ACT2 Study Group. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. *Cephalalgia*. 2018 Apr;38(5):959-969. doi: 10.1177/0333102417744362. Epub 2017 Dec 12.
60. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn BV, Gilmartin RC, Labar DR, Morris GL 3rd, Salinsky MC, Osorio I, Ristanovic RK, Labiner DM, Jones JC, Murphy JV, Ney GC, Wheless JW. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. *Neurology*. 1998 Jul;51(1):48-55. doi: 10.1212/wnl.51.1.48. PMID: 9674777.
61. Handforth A, Ondo WG, Tatter S, Mathern GW, Simpson RK Jr, Walker F, Sutton JP, Hubble JP, Jankovic J. Vagus nerve stimulation for essential tremor: a pilot efficacy and safety trial. *Neurology*. 2003 Nov 25; 61(10): 1401-5.
62. Hayes, Inc. Emerging Technology Report. Vivistim Paired VNS System for Stroke Rehabilitation. August 2021. © 2021 Hayes, a symplr Company.
63. Hayes, Inc. Hayes Medical Technology Directory. Vagus Nerve Stimulation for Epilepsy. Lansdale, PA: Hayes, Inc.; Dec 2007.
64. Hayes, Inc. Hayes Medical Technology Directory. Vagus Nerve Stimulation for Depression. Lansdale, PA: Hayes, Inc.; Oct 2005. Updated May 2007.
65. Henssen DJHA, Derks B, van Doorn M, et al. Vagus nerve stimulation for primary headache disorders: An anatomical review to explain a clinical phenomenon. *Cephalalgia*. 2019 Aug;39(9):1180-1194. doi: 10.1177/0333102419833076. Epub 2019 Feb 20.
66. Holle-Lee D, Gaul C. Noninvasive vagus nerve stimulation in the management of cluster headache: clinical evidence and practical experience. *Ther Adv Neurol Disord*. 2016 May;9(3):230-4.
67. Kimberley TJ, Pierce D, Prudente CN, Francisco GE, et al. Vagus nerve stimulation paired with upper limb rehabilitation after chronic stroke: A blinded randomized pilot study. *Stroke*. 2018 Nov;49(11):2789-92.
68. Kong J, Fang J, Park J, Li S, Rong P. Treating Depression with Transcutaneous Auricular Vagus Nerve Stimulation: State of the Art and Future Perspectives. *Front Psychiatry*. 2018;9:20. Published 2018 Feb 5. Doi:10.3389/fpsy.2018.00020.
69. Korupolu R, Miller A, Park A, Yozbatiran N. Neurorehabilitation with vagus nerve stimulation: a systematic review. *Front Neurol*. 2024 May 30;15:1390217. doi: 10.3389/fneur.2024.1390217.
70. Lange G, Janal MN, Maniker A, Fitzgibbons J, Fobler M, Cook D, Natelson BH. Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial. *Pain Med*. 2011 Sep;12(9):1406-13.
71. Lerman I, Davis B, Huang M, Huang C, Sorkin L, Proudfoot J, Zhong E, Kimball D, Rao R, Simon B, Spadoni A, Strigo I, Baker DG, Simmons AN. Noninvasive vagus nerve stimulation alters neural response and physiological autonomic tone to noxious thermal challenge. *PLoS One*. 2019 Feb 13;14(2):e0201212. doi: 10.1371/journal.pone.0201212.
72. Liu A, Rong P, Gong L, et al. Efficacy and Safety of Treatment with Transcutaneous Vagus Nerve Stimulation in 17 Patients with Refractory Epilepsy Evaluated by Electroencephalogram, Seizure Frequency, and Quality of Life. *Med Sci Monit*. 2018;24:8439–8448. Published 2018 Nov 23. Doi:10.12659/MSM.910689.

73. Liu CY, Russin J, Adelson DP, Jenkins A, et al. Vagus nerve stimulation paired with rehabilitation for stroke: Implantation experience from the VNS-REHAB trial. *J Clin Neurosci*. 2022 Nov;105:122-128. doi: 10.1016/j.jocn.2022.09.013. Epub 2022 Sep 28. PMID: 36182812.
74. Lo JW, Crawford JD, Desmond DW, Bae HJ, et al; Stroke and Cognition (STROKOG) Collaboration. Long-Term Cognitive Decline After Stroke: An Individual Participant Data Meta-Analysis. *Stroke*. 2022 Apr;53(4):1318-1327. doi: 10.1161/STROKEAHA.121.035796. Epub 2021 Nov 15.
75. Marano M, Magee R, Blasi F, Anzini G, Capone F, Ricciuti R, Ottaviani MM, Di Lazzaro V. An open-label pilot study of non-invasive cervical vagus nerve stimulation in essential tremor. *Brain Stimul*. 2024 Nov-Dec;17(6):1283-1285. doi: 10.1016/j.brs.2024.11.008. Epub 2024 Nov 18.
76. Marin J, Giffin N, Consiglio E, McClure C, Liebler E, Davies B. Non-invasive vagus nerve stimulation for treatment of cluster headache: early UK clinical experience. *J Headache Pain*. 2018 Nov 23;19(1):114. doi: 10.1186/s10194-018-0936-1.
77. Martelletti P, Jensen RH, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. *J Headache Pain*. 2013 Oct 21;14:86.
78. McGlone J, Valdivia I, Penner M, Williams J, Sadler RM, Clarke DB. Quality of life and memory after vagus nerve stimulator implantation for epilepsy. *Can J Neurol Sci*. 2008 Jul; 35(3):287-96.
79. Meneses MS, Rocha SF, Simão C, Santos HN, Pereira C, Kowacs PA. Vagus nerve stimulation may be a sound therapeutic option in the treatment of refractory epilepsy. *Arq Neuropsiquiatr*. 2013 Jan;71(1):25-30.
80. Min B, Jian Z, Guo-ming L. Treatment of drug-resistant epilepsy with vagus nerve stimulation: review of 45 cases. *Chin Med J* 2011;124(24):4184-4188.
81. Nahas Z, Marangell LB, Husain MM, Rush AJ, Sackeim HA, Lisanby SH, Martinez JM, George MS. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. *J Clin Psychiatry*. 2005 Sep; 66(9): 1097-104.
82. National Institute for Health and Clinical Excellence (NICE). Interventional Procedure Guidance (IPG) 050: Vagus nerve stimulation for refractory epilepsy in children. 24 March 2004. Accessed at <http://www.nice.org.uk/> on 04/22/13.
83. National Institute for Health and Clinical Excellence (NICE). Interventional Procedure Guidance (IPG) 330: Vagus nerve stimulation for treatment-resistant depression. 16 December 2009.. Accessed at <http://www.nice.org.uk/>.
84. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline (CG) 137: The Epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. 11 January 2012. Accessed at <http://www.nice.org.uk/>.
85. National Institute for Health and Care Excellence (NICE). Interventional procedures guidance (IPG) 552: Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (March 2016). Accessed at <http://www.nice.org.uk/>.
86. National Institute for Health and Care Excellence (NICE). Medical technologies guidance [MTG46]: gammaCore for cluster headache (December 2019). Accessed at <http://www.nice.org.uk/>.
87. National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults (NG217) (April 2022).
88. Nemeroff CB, Mayberg HS, Krahl SE, McNamara J, Frazer A, Henry TR, George MS, Charney DS, Brannan SK. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. *Neuropsychopharmacology*. 2006 Jul; 31(7): 1345-55.
89. NeurosurgeryToday.org. Treatment-Resistant Depression (TRD). Vagus Nerve Stimulation. (May 2007).

90. Nonis R, D'Ostilio K, Schoenen J, Magis D. Evidence of activation of vagal afferents by non-invasive vagus nerve stimulation: An electrophysiological study in healthy volunteers. *Cephalalgia*. 2017 Nov;37(13):1285-1293. doi: 10.1177/0333102417717470. Epub 2017 Jun 26.
91. Papasavas P, El Chaar M, Kothari SN; American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. American Society for Metabolic and Bariatric Surgery position statement on vagal blocking therapy for obesity. *Surg Obes Relat Dis*. 2016;12(3):460–461. Doi:10.1016/j.soard.2015.12.004.
92. Parhizgar F, Nugent, K, Raj R. Obstructive Sleep Apnea and Respiratory Complications Associated with Vagus Nerve Stimulators. *Clin Sleep Med* 2011;7(4):401-407.
93. Pelot NA, Grill WM. Effects of vagal neuromodulation on feeding behavior. *Brain Res*. 2018;1693(Pt B):180–187. Doi:10.1016/j.brainres.2018.02.003.
94. Privitera MD, Welty TE, Ficker DM, Welge J. Vagus nerve stimulation for partial seizures. *The Cochrane Database of Systematic Reviews* 2002, Issue 1. Art. No.: CD002896. DOI: 10.1002/14651858.CD002896.
95. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. *Biol Psychiatry*. 2004 Feb 1; 55(3): 301-12.
96. Ramos-Castaneda JA, Barreto-Cortes CF, Losada-Florian D, Sanabria-Barrera SM, Silva-Sieger FA, Garcia RG. Efficacy and Safety of Vagus Nerve Stimulation on Upper Limb Motor Recovery After Stroke. A Systematic Review and Meta-Analysis. *Front Neurol*. 2022 Jul 1;13:889953. doi: 10.3389/fneur.2022.889953.
97. Reuter U, McClure C, Liebler E, Pozo-Rosich P. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. *J Neurol Neurosurg Psychiatry*. 2019 Jul;90(7):796-804. doi: 10.1136/jnnp-2018-320113. Epub 2019 Mar 1.
98. Robbins MS, et al. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. *Headache*. 2016; 56(7):1093-1106.
99. Rong PJ, Fang JL, Wang LP, Meng H, Liu J, Ma YG, Ben H, Li L, Liu RP, Huang ZX, Zhao YF, Li X, Zhu B, Kong J. Transcutaneous vagus nerve stimulation for the treatment of depression: a study protocol for a double blinded randomized clinical trial. *BMC Complement Altern Med*. 2012 Dec 14;12:255.
100. Rush AJ, Conway CR, Aaronson ST, George MS, Riva-Posse P, Dunner DL, Zajecka J, Bunker MT, Quevedo J, Allen RM, Alva G, Luing H, Nahas Z, Manu L, Bennett JI, Mickey BJ, Becker J, Sheline Y, Cusin C, Murrough JW, Reeves K, Rosenquist PB, Lee YL, Majewski S, Way J, Olin B, Sackeim HA. Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. *Brain Stimul*. 2025 May-Jun;18(3):690-700. doi: 10.1016/j.brs.2024.12.1187. Epub 2024 Dec 18.
101. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. *Biol Psychiatry*. 2005 Sep 1; 58(5): 347-54.
102. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. *Biol Psychiatry*. 2005 Sep 1; 58(5): 355-63.
103. Sant'Anna LB, Couceiro SLM, Ferreira EA, Sant'Anna MB, Cardoso PR, Mesquita ET, Sant'Anna GM, Sant'Anna FM. Vagal Neuromodulation in Chronic Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. *Front Cardiovasc Med*. 2021 Nov 24;8:766676. doi: 10.3389/fcvm.2021.766676.
104. Shafique S, Dalsing MC. Vagus nerve stimulation therapy for treatment of drug-resistant epilepsy and depression. *Perspect Vasc Surg Endovasc Ther*. 2006 Dec; 18(4): 323-7; discussion 328.

105. Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ. The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations. *Am J Manag Care*. 2017 Nov;23(17 Suppl):S326-S333.
106. Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, Rubenstein Engel E, Tepper SJ; ACT1 Study Group. Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study. *Headache*. 2016 Sep;56(8):1317-32. doi: 10.1111/head.12896.
107. Silberstein SD, Yuan H, Najib U, Ailani J, Morais AL, Mathew PG, Liebler E, Tassorelli C, Diener HC. Non-invasive vagus nerve stimulation for primary headache: A clinical update. *Cephalalgia*. 2020 Oct;40(12):1370-1384. doi: 10.1177/0333102420941864. Epub 2020 Jul 27.
108. Simon B, Blake J. Mechanism of action of non-invasive cervical vagus nerve stimulation for the treatment of primary headaches. *Am J Manag Care*. 2017 Nov;23(17 Suppl):S312-S316.
109. Terra VC, Nisyiama MA, Abrão J, Sakamoto AC, Machado HR, Arida RM, Cavalheiro EA, Scorza FA. Epileptologists probe vagus nerve stimulation in children with refractory epilepsy: a promise against sudden unexpected death in epilepsy. *Arq Neuropsiquiatr*. 2012 Dec;70(12):953-5.
110. United States Food and Drug Administration (FDA). DeNovo Summary DEN150048: gammaCore Non-invasive Vagus Nerve Stimulator. September 1, 2017. Accessed at <https://www.accessdata.fda.gov/>.
111. United States Food and Drug Administration (FDA). 510(k) Summary K203546: gammaCore Sapphire. Regulation Number: 21 CFR 882.5892. Accessed at <https://www.accessdata.fda.gov/>.
112. UpToDate. Bipolar disorder in adults: Overview of neuromodulation procedures. 2025. Accessed at uptodate.com.
113. UpToDate. Cluster headache: Treatment and prognosis. 2025. Accessed at uptodate.com.
114. UpToDate. Management of treatment-resistant, severe major depression in adults. 2025. Accessed at uptodate.com.
115. UpToDate. Overview of ischemic stroke prognosis in adults. 2025. Accessed at uptodate.com.
116. UpToDate. Unipolar depression in adults: Overview of neuromodulation procedures. 2025. Accessed at uptodate.com.
117. UpToDate. Vagus nerve stimulation therapy for the treatment of epilepsy. 2025. Accessed at uptodate.com.
118. Urits I, Schwartz R, Smoots D, et al. Peripheral Neuromodulation for the Management of Headache. *Anesth Pain Med*. 2020 Nov 30;10(6):e110515. doi: 10.5812/aapm.110515.
119. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. *Circulation*. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29. PMID: 31992061.
120. Wu Q, Wang J, Han D, Qian L, Hu H, Gao H. Current status of transcutaneous auricular vagus nerve stimulation for tinnitus: a narrative review of modern research. *Front Neurosci*. 2024 Jul 4;18:1405310. doi: 10.3389/fnins.2024.1405310.
121. Yousufuddin M, Moriarty JP, Lackore KA, et al. Initial and subsequent 3-year cost after hospitalization for first acute ischemic stroke and intracerebral hemorrhage. *J Neurol Sci*. 2020 Dec 15;419:117181. doi: 10.1016/j.jns.2020.117181. Epub 2020 Oct 18. PMID: 33099173.
122. Zhao T, Schiweck C, Jamalambadi H, Meyer K, Brandt E, Schneider M, Aichholzer M, Qubad M, Bouzouina A, Schillo S, Hanssen R, Sonkusare S, Kingslake J, Beckenstrom A, Repple J, Reif-Leonhard C, Hahn T, Reif A, Edwin Thanarajah S. Transcutaneous vagus nerve stimulation

improves emotional processing. J Affect Disord. 2025 Mar 1;372:96-105. doi: 10.1016/j.jad.2024.11.077. Epub 2024 Nov 28.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 01/22/26.

GUIDELINE UPDATE INFORMATION:

06/15/00	New Medical Coverage Guideline.
08/23/01	Review of guideline with no revisions.
06/15/02	Revised to delete age limitation.
06/15/03	Review of guideline with no changes in coverage.
06/15/04	Review and revision of guideline; consisting of updated references.
01/01/05	Annual HCPCS update; consisting of the revision of 61885, 61886 and 64590.
04/15/05	Review and revision of guideline; consisting of updated references.
04/15/06	Review and revision of guideline consisting of updated references.
01/01/07	HCPCS coding update consisting of the revision of 64590 and 64595.
06/15/07	Review and revision of guideline consisting of updated references and reformatted guideline.
04/15/08	Review and revision of guideline consisting of updated references.
06/15/09	Scheduled review; no change to position statement. Update references.
01/01/10	Annual HCPCS coding review: revise descriptor for CPT code 61886.
06/15/10	Biennial review; no change in position statement. References updated.
01/01/11	Annual HCPCS coding update. Added codes 64568, 64569 and 64570; deleted code 64573.
01/01/12	Annual HCPCS coding update. Revised 64553, 95974 and 95975 descriptors.
06/15/12	Scheduled review. Revised description section and position statement (added additional indications which are considered experimental/investigational); revised Medicare Advantage program exception and updated references.
01/01/13	Annual CPT coding update. Added codes 0312T, 0313T, 0314T, 0315T, 0316T and 0317T.
06/15/13	Scheduled review. Revised description, position statement and program exceptions section. Updated references and reformatted guideline.
11/15/17	Unscheduled review. Maintained position statement. Revised CPT coding and program exceptions section. Updated references and reformatted guideline.
01/01/18	Annual CPT/HCPCS coding update: revised 64550.
01/01/19	Annual CPT/HCPCS coding update. Deleted 64550, 95974, 95975.
03/15/20	Scheduled review. Revised description and position statement. Updated references.
04/01/21	Quarterly CPT/HCPCS coding update. Added code K1020.
01/01/21	Annual CPT/HCPCS coding update. Revised descriptor 64568.
02/15/22	Scheduled review. Maintained position statement and updated references.
01/01/23	Annual CPT/HCPCS coding update. Deleted 0312T, 0313T, 0314T, 0315T, 0316T, 0317T.
02/15/23	Revision. Updated references and maintained position statement.

05/25/23	Update to Program Exceptions section.
01/01/24	Annual CPT/HCPCS coding update. Added E0735; deleted K1020.
02/15/24	Scheduled review. Revised description, maintained position statements, and updated references.
01/01/25	Annual CPT/HCPCS coding update. Added 0908T, 0909T, 0910T, 0911T, 0912T.
02/15/25	Scheduled review. Revised description and position statement (added autoimmune disease to list of conditions considered E/I). Updated references.
01/01/26	Annual CPT/HCPCS coding update. Added C1607.
02/15/26	Scheduled review. Maintained position statements and updated references.